This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Soleno Therapeutics Faces Securities...
Regulatory class action lawsuit

Soleno Therapeutics Faces Securities Fraud Lawsuit

Analysis based on 15 articles · First reported Mar 09, 2026 · Last updated Mar 13, 2026

Sentiment
-20
Attention
2
Articles
15
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The market is negatively impacted by the news of a class action lawsuit against Soleno Therapeutics, potentially leading to a decrease in its stock price. This event highlights the risks associated with clinical trial disclosures in the biotechnology sector.

Biotechnology Legal Services
Event Summary

The Schall Law Firm has initiated a class action lawsuit against Soleno Therapeutics, Inc. for alleged violations of securities laws. The lawsuit claims that Soleno Therapeutics made false and misleading statements to investors between March 26, 2025, and November 4, 2025, regarding its diazoxide choline extended-release tablets (DCCR). Specifically, the company is accused of downplaying safety concerns and overstating the commercial viability of its DCCR treatment, which allegedly suffered from greater safety risks and lower commercial potential than disclosed. Investors who purchased Soleno Therapeutics' securities during this period and suffered losses are encouraged to join the lawsuit.

Key Actions
95 The Schall Law Firm filed a class action lawsuit Soleno Therapeutics
90 Soleno Therapeutics made false and misleading statements
Entities Involved
stock
Soleno Therapeutics
Soleno Therapeutics is facing a class action lawsuit for allegedly making false and misleading statements regarding the safety and commercial viability of its DCCR treatment. This could lead to significant financial penalties and reputational damage for the company.
Importance 90 Sentiment -50
priv
The Schall Law Firm
The Schall Law Firm is initiating and representing investors in a class action lawsuit against Soleno Therapeutics, aiming to recover losses for shareholders. This event enhances the firm's visibility and business.
Importance 70 Sentiment 20
per
Brian Schall
Brian Schall is the contact person for The Schall Law Firm regarding the class action lawsuit against Soleno Therapeutics. His involvement is central to the firm's actions in this event.
Importance 40 Sentiment 10
govactor
United States===United States Securities and Exchange Commission
The United States===United States Securities and Exchange Commission promulgates the rules (Rule 10b-5) under which the class action lawsuit against Soleno Therapeutics is being filed, indicating its regulatory oversight.
Importance 30 Sentiment 0
exch
Nasdaq
Nasdaq is the stock exchange where Soleno Therapeutics' shares are traded, making it the venue where investors suffered losses due to the alleged misleading statements.
Importance 10 Sentiment 0
Relationships
The Schall Law Firm related ↔ Soleno Therapeutics
Brian Schall related ↔ The Schall Law Firm
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.